Expand DNLI Menu
DNLI MENU

DNLI Latest Press Releases

-- May 21, 2026 --

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease Globe Newswire 6:00 PM

-- May 7, 2026 --

Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights Globe Newswire 4:01 PM

-- April 20, 2026 --

When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech Globe Newswire 8:30 AM

-- April 3, 2026 --

Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN) Globe Newswire 1:30 PM

-- March 25, 2026 --

Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II) Globe Newswire 11:50 AM

-- February 26, 2026 --

Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Globe Newswire 4:01 PM

-- February 19, 2026 --

Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development Globe Newswire 8:30 AM

-- February 5, 2026 --

Denali Therapeutics Presents Enzyme TransportVehicle Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium Globe Newswire 2:00 PM

-- February 2, 2026 --

Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle Programs at the 2026 WORLDSymposium Globe Newswire 8:00 AM

-- January 29, 2026 --

Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium Globe Newswire 4:00 PM

-- January 6, 2026 --

Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome Globe Newswire 8:00 AM

-- December 30, 2025 --

The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II) Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes